Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients

References

• Fischl MA, Richman DD, Grieco MH et al. The efficacy of 3’-azido-3'deoxythymidine (azidothymidine) in the treatment of patients with AIDS and AIDS-related complex: a double-blind, placebo-controlled trial. N. Engl. J. Med.317, 185–191 (1987).
   PubMed Web of Science ®Google Scholar
• Gazzard B, on behalf of the BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviraltherapy. HIV Med.6(Suppl. 2), 1–61 (2005).
   PubMed Web of Science ®Google Scholar
• Iribarren JA, Labarga P, Rubio R et al. [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]. Enferm. Infecc. Microbiol. Clin.22, 564–642 (2004).
   PubMed Web of Science ®Google Scholar
• Bartlett J, Fath M, DeMasi R, Quinn J, Hermes A, Rousseau F. An Updated Meta-analysis of Triple Combination Therapy in Antiretroviral-naive HIV-infected Adults. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. February 22–25, Boston MA, USA, 2005, Abstract 586.
   Google Scholar
• Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev. Anti Infect. Ther.5, 671–684 (2004).
   Google Scholar
• Clay PG, Dong BJ, Sorensen SJ, Tseng A, Romanelli F, Antoniou T. Advances in human immunodeficiency virus therapeutics. Ann. Pharmacother.40, 704–709 (2006).
   PubMedGoogle Scholar
• Vivet-Boudou V, Didierjean J, Isel C, Marquet R. Nucleoside and nucleotide inhibitors of HIV-1 replication. Cell. Mol. Life Sci.63, 163–186 (2006).
   PubMed Web of Science ®Google Scholar
• Gallant JE, Gerondelis PZ, Wainberg MA et al. Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance. Antivir. Ther.8, 489–506 (2003).
   PubMed Web of Science ®Google Scholar
• Jones R, Sawleshwarkar S, Michailidis C et al. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone. HIV Med.6, 396–402 (2005).
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Miggliorino M, Maserati R et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir. Ther.6, 249–253 (2001).
   PubMed Web of Science ®Google Scholar
• Landman R, Schiemann R, Thiam S et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS17, 1017–1022 (2003).
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Gregis G et al. Once-a-day therapy for HIV infection: a controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir. Ther.8, 339–346 (2003).
   PubMed Web of Science ®Google Scholar
• Saag MS, Cahn P, Raffi F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial. JAMA292, 180–189 (2004).
   PubMed Web of Science ®Google Scholar
• Molina JM, Ferchal F, Racinan C et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J. Infect. Dis.182, 599–602 (2000).
   PubMed Web of Science ®Google Scholar
• DeJesus E, Ward D, Cohen C et al. Efficacy and safety of a once-daily efavirenz (EFV)-based regimen for treatment of naive HIV subjects: 96 week results from the DART study. Program and abstracts of the European AIDS Clinical Society 10th European AIDS Conference. November 17–20, 2005. Dublin, Ireland. Abstract PE 7.3/3.
   Google Scholar
• Maggiolo F, Ripamonti D, Migliorino G et al. Three once-a-day regimens as first-line HAART. Program and abstracts of the 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24–27, 2005, Rio de Janeiro, Brazil. Abstract WePe12.2C04.
   Google Scholar
• Maitland D, Moyle G, Hand J et al. Early virologic failure in HIV-1 infected subjects on didanosine/tenofovir/efavirenz: 12-week results from a randomized trial. AIDS19, 1183–1188 (2005).
   PubMed Web of Science ®Google Scholar
• Santos J, Palacios R, López M et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: the VESD study. HIV Clin. Trials6, 320–328 (2005).
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewki S, Pozniak AL et al. 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA292, 191–201 (2004).
   PubMed Web of Science ®Google Scholar
• Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N. Engl. J. Med.354, 251–260 (2006).
   PubMed Web of Science ®Google Scholar
• DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin. Infect. Dis.39, 1038–1046 (2004).
   PubMed Web of Science ®Google Scholar
• Carr A, Cooper D. Adverse effects of antiretroviral therapy. Lancet356, 1423–1430 (2000).
   PubMed Web of Science ®Google Scholar
• Walker UA. Update on mitochondrial toxicity: where are we now? J. HIV Ther.8, 32–35 (2003).
   PubMedGoogle Scholar
• Cherry CL, Nolan D, James IR et al. Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals. J. Acquir. Immune Defic. Syndr.42, 435–440 (2006).
   PubMed Web of Science ®Google Scholar
• Perronne C. Antiviral hepatitis and antiretroviral drug interactions. J. Hepatol.44(Suppl. 1), S119–S125 (2006).
   PubMedGoogle Scholar
• Moreno A, Quereda C, Moreno L et al. High rate of didanosine-related mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin. Antivir. Ther.9, 133–138 (2004).
   PubMed Web of Science ®Google Scholar
• Laguno M, Milinkovic A, de Lazzari E et al. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCV-coinfected patients. Antivir. Ther.10, 423–429 (2005).
   PubMedGoogle Scholar
• Hsu RK, Wainberg MA. Do new protease inhibitors offer improved sequencing options? Issues of PI resistance and sequencing. J. Acquir. Immune Defic. Syndr.35(Suppl. 1), S13–S21 (2004).
   Google Scholar
• Kempf D, King M, Bernstein B et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J. Infect. Dis.189, 51–60 (2004).
   PubMed Web of Science ®Google Scholar
• Eron JJ Jr. The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS10(Suppl. 5), S11–S19 (1996).
   PubMed Web of Science ®Google Scholar
• Melby T, Tortell S, Thorborn D et al. Time to appearance of NRTI-associated mutations and response to subsequent therapy for patients on failing ABC/COM. Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. February 4–8, 2001, Chicago, Illinois, USA. Abstract 448.
   Google Scholar
• Farthing C, Khanlou H, Yeh V. Early virologic failure in a pilot study evaluating the efficacy of abacavir, lamivudine and tenofovir in the treatment naive HIV-infected patients. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. July 13–16, 2003, Paris, France. Abstract 43.
   Google Scholar
• Landman R, Peytavin G, Descamps D et al. Low genetic barrier to resistance is a possible cause of early virologic failures in once-daily regimen of abacavir, lamivudine, and tenofovir: the Tonus study. Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections. February 8–11, 2004, San Francisco, CA, USA. Abstract 52.
   Google Scholar
• Ruane P, Luber A, Akil B et al. Factors influencing selection of K65R mutation among patients receiving tenofovir (TDF) containing regimens. Program and abstracts of the 2nd IAS Conference on HIV Pathogenesis and Treatment. July 13–16, 2003, Paris, France. Abstract 582.
   Google Scholar
• D'Aquila RT, Schapiro JM, Brun-Vezinet F et al. Drug resistance mutations in HIV-1. Top. HIV Med.11, 92–96 (2003).
   PubMedGoogle Scholar
• Hirsch MS, Brun-Vezinet F, Clotet B et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin. Infect. Dis.37, 113–128 (2003).
   PubMed Web of Science ®Google Scholar
• Lanier R, Irlbeck D, Ross L et al. Prediction of NRTI options by linking reverse transcriptase genotypes to phenotypic breakpoints. Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections. February 10–14, 2003, Boston, MA, USA. Abstract 586.
   Google Scholar
• Marcelin AG, Flandre P, Pavie J et al. AI454–176 Jaguar Study Team. Clinically relevant genotype interpretation of resistance to didanosine. Antimicrob. Agents Chemother.49, 1739–1744 (2005).
   PubMed Web of Science ®Google Scholar
• Flandre P, Marcelin AG, Pavie J et al. Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study. Antivir. Ther.10, 479–487 (2005).
   PubMedGoogle Scholar
• Knobel H. [Quality of life, satisfaction, adherence and effectivity to antiretroviral treatment]. Enferm. Infecc. Microbiol. Clin.23, 579–580 (2005).
   PubMedGoogle Scholar
• Paterson DL, Swindells S, Mohr J et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med.133, 21–30 (2000).
   PubMed Web of Science ®Google Scholar
• Moyle G. Once-daily therapy: less is more. Int. J. STD AIDS14(Suppl. 1), 1–5 (2003).
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Suter F. Once-a-day HAART: dream or reality? HIV Clin. Trials4, 193–201 (2003).
   PubMed Web of Science ®Google Scholar
• Jordan J, Cahn P, Goebel F, Matheron S, Bradley C, Woodcock A. Abacavir compared to protease inhibitors as part of HAART regimens for treatment of HIV infection: patient satisfaction and implications for adherence. AIDS Patient Care STDS19, 9–18 (2005).
   PubMed Web of Science ®Google Scholar
• Stone VE, Jordan J, Tolson J, Miller R, Pilon T. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J. Acquir. Immune Defic. Syndr.36, 808–816 (2004).
   PubMed Web of Science ®Google Scholar
• Pulido F, Ribera E, Moreno S et al. Once-daily antiretroviral therapy: Spanish Consensus Statement. J. Antimicrob. Chemother.5, 808–818 (2005).
   Google Scholar
• Knobel H, Guelar A. [Strategies to optimize adherence to antiretroviral treatment. Interventions in the therapeutic regimen]. Enferm. Infecc. Microbiol. Clin.22, 106–112 (2004).
   PubMed Web of Science ®Google Scholar
• Palacios R, del Arco A, Grana M et al. Adherence and quality of life with a once-daily antiretroviral regimen with didanosine (ddI), lamivudine (3TC) and efavirenz (EFV) in naïve patients. The VESD study. Abstract WePe12.2C05. 3rd IAS Conference on HIV Pathogenesis and Treatment. July 24–27, 2005. Río de Janeiro, Brazil.
   Google Scholar
• Merito M, Pezzotti P, for the ICONA Study Group. Comparing costs and effectiveness of different starting points for highly active antiretroviral therapy in HIV-positive patients Evidence from the ICONA cohort. Eur. J. Health Econ.1, 30–36 (2006).
   Google Scholar
• Colebunders R, Florence E, Lynene L, Bouckenooghe A. Highly active antiretroviral treatment in countries with very limited resources: do we have cheaper alternatives? Int. J. STD AIDS14, 1–5 (2003).
   PubMedGoogle Scholar